Brimonidine tartrate is under clinical development by Visiox Pharma and currently in Pre-Registration for Ocular Hypertension. According to GlobalData, Pre-Registration drugs for Ocular Hypertension have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Brimonidine tartrate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Brimonidine tartrate overview

Brimonidine tartrate is under development for the treatment of open-angle glaucoma and ocular hypertension. It is formulated as ophthalmic solution administered once a day (OD) as eye drops. The drug candidate targets alpha 2 adrenergic receptor. It is developed based on TearAct technology. The technology involves drug-resin complex suspension which provides slow, consistent and sustained exposure.

Visiox Pharma overview

Visiox Pharma (Visiox) is focused on developing ophthalmic drugs. Visiox is headquartered in the US.

For a complete picture of Brimonidine tartrate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.